Alan Anderson, MD
Pediatric Hematology-Oncology · Greenville, SCNPI 1124175146
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Global Blood Therapeutics, Inc. accounts for 74.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $115,006 and has fallen 78.9% since, to $24,317 in 2025. Among pediatric hematology-oncology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $836.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$239K
- Pfizer$62K
- Agios Pharmaceuticals, Inc.$10K
- RARE Disease Therapeutics, Inc.$4K
- Novartis$2K
- Orthopediatrics Corp.$2K
- plus $2K from 23 others
Across 41 payments — averaging $18,618 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$638K
- Pfizer$57K
- Global Blood Therapeutics, Inc.$50K
- Agios Pharmaceuticals, Inc.$14K
- Novo Nordisk AS$5K
What the payments were for
- Royalty or licence$1,9951%
- Consulting fees$119,62837%
- Speaking & faculty fees$176,31755%
- Travel & lodging$16,5305%
- Food & beverage$5,2022%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 238 | $238,675 |
| Pfizer | 63 | $62,081 |
| Agios Pharmaceuticals, Inc. | 14 | $9,683 |
| RARE Disease Therapeutics, Inc. | 2 | $3,519 |
| Novartis | 15 | $1,995 |
| Orthopediatrics Corp. | 5 | $1,995 |
| Vertex | 2 | $667 |
| Novo Nordisk | 7 | $233 |
| CSL Behring | 7 | $144 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $110 |
| Puma Biotechnology, Inc. | 1 | $94 |
| Sanofi | 3 | $80 |
| Pierre Fabre Pharmaceuticals, Inc. | 3 | $57 |
| Bayer | 3 | $57 |
| Genentech USA, Inc. | 2 | $45 |
| Terumo BCT, Inc. | 3 | $36 |
| Adaptive Biotechnologies Corporation | 1 | $34 |
| Kedrion Biopharma, Inc. | 1 | $24 |
| Biomarin Pharmaceutical Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Duchesnay USA Incorporated | 1 | $17 |
| Y-mabs Therapeutics, Inc. | 1 | $17 |
| Silvergate Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
| Mylan Institutional Inc. | 1 | $13 |
| Emmaus Medical, Inc. | 1 | $12 |
| Octapharma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$319,709 in reported general payments places this provider in the 95th percentile of 32 pediatric hematology-oncology providers in South Carolina.
See all pediatric hematology-oncology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxbrytaVoxelotor | 35 | $422,040 |
| Deferasirox | 42 | $71,768 |
| EndariGlutamine | 21 | $60,926 |
| OxycontinOxycodone Hcl | 28 | $34,786 |
| Buprenorphine | 21 | $6,007 |
| Morphine Sulfate ErMorphine Sulfate | 68 | $3,260 |
| Oxycodone Hcl | 113 | $2,956 |
| Hydromorphone Hcl | 70 | $1,774 |
| Methadone Hcl | 38 | $829 |
| Hydroxyurea | 44 | $746 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $676 |
| Promethazine Hcl | 28 | $434 |
| Cyclobenzaprine Hcl | 67 | $400 |
| Gabapentin | 31 | $359 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 27 | $327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Global Blood Therapeutics, Inc.Oxbryta | $238,675 | $422,04035 claims |
| Emmaus Medical, Inc.Endari | $12 | $60,92621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 32 pediatric hematology-oncology providers in South Carolina.
Other pediatric hematology-oncology in Greenville
- Howland CrosswellGreenville$14K
- Leslie GilbertGreenville$8K
- Brianna MurphyGreenville$4K
- Nichole BryantGreenville$4K
- Aniket SahaGreenville$1K
- Rebecca CookGreenville$1K
- Chandni DarganGreenville$924
- Stephen MartinGreenville$699
- William SchmidtGreenville$0
- Shayla BergmannBeaufort$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.